Apotex Decries Biosimilar Notice Ruling At Fed. Circ.
Apotex is urging the Federal Circuit to reverse a district court's ruling that biosimilar makers must always give 180-day notice of sales to brand-name rivals, arguing that the decision wrongly extends...To view the full article, register now.
Already a subscriber? Click here to view full article